IAM
NKTR icon

Iridian Asset Management’s Nektar Therapeutics NKTR Stock Holding History

Iridian Asset Management’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.25M Buy
31,320
+21,592
+222% +$1.23M 0.91% 29
2025
Q4 		$411K Buy
+9,728
New +$544K 0.15% 41

Other funds holding NKTR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Iridian Asset Management's NKTR Position: Q1 2026 in Review

Iridian Asset Management increased its Nektar Therapeutics (NKTR) stake by 222% in Q1 2026, buying an estimated $1.23M and bringing the position to 31,320 shares worth $2.25M. The position accounts for 0.91% of the portfolio, ranked #29.

Iridian Asset Management first reported a position in NKTR in Q4 2025 and has held it in 2 quarters since. 215 funds tracked by Wall St. Rank hold NKTR as of Q1 2026.

  • Iridian Asset Management held 31,320 shares of Nektar Therapeutics worth $2.25M as of Q1 2026.
  • Iridian Asset Management bought 21,592 Nektar Therapeutics shares in Q1 2026, an estimated $1.23M.
  • Nektar Therapeutics made up 0.91% of Iridian Asset Management's portfolio in Q1 2026, its #29 holding.
  • Iridian Asset Management first reported a position in Nektar Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • 215 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q1 2026.

Based on Iridian Asset Management's 13F filing for Q1 2026, filed 24 Apr 2026.